| Market Cap | 330.36M | P/E | - | EPS this Y | -216.00% | Ern Qtrly Grth | - |
| Income | -58.07M | Forward P/E | -2.21 | EPS next Y | 13.90% | 50D Avg Chg | 6.00% |
| Sales | 378k | PEG | - | EPS past 5Y | - | 200D Avg Chg | -6.00% |
| Dividend | N/A | Price/Book | 1.39 | EPS next 5Y | - | 52W High Chg | -60.00% |
| Recommedations | 1.90 | Quick Ratio | 5.13 | Shares Outstanding | 167.80M | 52W Low Chg | 75.00% |
| Insider Own | 9.99% | ROA | -27.97% | Shares Float | 128.63M | Beta | 0.79 |
| Inst Own | 27.09% | ROE | -31.51% | Shares Shorted/Prior | 9.63M/9.57M | Price | 1.99 |
| Gross Margin | 100.00% | Profit Margin | - | Avg. Volume | 992,638 | Target Price | 11.60 |
| Oper. Margin | -9,424.54% | Earnings Date | Nov 5 | Volume | 461,009 | Change | -2.93% |
Atai Life Sciences N.V., a clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its product candidates include COMP360, a proprietary psilocybin which is in Phase 3 program; BPL-003, an intranasal formulation that is in Phase 2a and 2b clinical studies; TRD; VLS-01, an transmucosal film in Phase 1b clinical studies; and ELE-101, a serotonergic psychedelic that is in Phase 1/2a study, for the treatment of treatment resistant depression. The company also develop IBX-210, an intravenous formulation of ibogaine, and DMX-1002, an oral formulation of ibogaine indicated for the treatment of opioid use disorder; EMP-01, an oral formulation of an R-MDMA derivative being developed for the treatment of post-traumatic stress disorder; and EGX-A and EGX-B, psychedelic-like with novel, non-tryptamine structures with differentiated 5-HT receptor pharmacology. In addition, it offers RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; and GRX-917, a deuterated etifoxine for the treatment of generalize anxiety disorder. Further, the company develops PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; KUR-101, a formulation of deuterated mitragynine for the treatment of OUD; and RLS-01, indicated for treatment resistant depression. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Brand Florian | See Remarks See Remarks | Nov 16 | Buy | 1.156 | 20,000 | 23,120 | 130,000 | 11/20/23 |
| Brand Florian | See Remarks See Remarks | Mar 29 | Buy | 1.4794 | 70,000 | 103,558 | 70,000 | 03/30/23 |
| Apeiron Investment Group Ltd. | 10% Owner 10% Owner | Apr 18 | Buy | 5.12 | 119,637 | 612,541 | 1,478,520 | 04/20/22 |
| Apeiron Investment Group Ltd. | 10% Owner 10% Owner | Apr 14 | Buy | 5.19 | 4,967 | 25,779 | 1,358,883 | 04/18/22 |
| Apeiron Investment Group Ltd. | 10% Owner 10% Owner | Apr 08 | Buy | 4.82 | 111,615 | 537,984 | 1,298,719 | 04/12/22 |